Cardiff Oncology, Inc. (CRDF) 2021年年度报告「NASDAQ」.pdf

1、UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549Form 10-K(Mark One)ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year ended December 31,2021TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934Fo

2、r the Transition Period from to Commission File Number:001-35558CARDIFF ONCOLOGY,INC.(Exact name of registrant as specified in its charter)Delaware27-2004382(State or other jurisdiction of incorporation or organization)(I.R.S.Employer Identification No.)11055 Flintkote Avenue,San Diego,California921

3、21(Address of principal executive offices)(Zip Code)(858)952-7570(Registrants telephone number,including area code)Securities registered pursuant to Section 12(b)of the Act:Title of each className of each exchange on which registeredCommon Stock,$0.0001 par valueThe NASDAQ Capital MarketSecurities r

4、egistered pursuant to Section 12(g)of the Act:NoneIndicate by check mark if the registrant is a well-known seasoned issuer,as defined in Rule 405 of the Securities Act.Yes No Indicate by check if the registrant is not required to file reports pursuant to Section 13 or Section 15(d)of the Act.Yes No

5、Indicate by check mark whether the registrant(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of 1934during the preceding 12 months(or for such shorter period that the registrant was required to file such reports),and(2)has been subject to such filin

6、grequirements for the past 90 days.Yes No Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site,if any,every Interactive Data File requiredto be submitted and posted pursuant to Rule 405 of Regulation S-T(232.405 of this chapter)during the pr